Drug
Candida Antigen
Candida Antigen is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph not_applicable
1
20%
Ph phase_1
1
20%
Ph phase_2
1
20%
Ph phase_3
2
40%
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(2)
Other(2)
Detailed Status
Completed2
unknown2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)
N/A1 (20.0%)
Trials by Status
completed240%
not_yet_recruiting120%
unknown240%
Recent Activity
0 active trials
Showing 5 of 5
not_yet_recruitingnot_applicable
Sclerotherapy and Candida Antigen in Treatment of Common Warts
NCT06749665
completedphase_2
Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts
NCT04399577
unknownphase_3
Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts
NCT03853785
unknownphase_3
Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts
NCT03158168
completedphase_1
Study With Candida Antigen for Treatment of Warts
NCT00569231
Clinical Trials (5)
Showing 5 of 5 trials
NCT06749665Not Applicable
Sclerotherapy and Candida Antigen in Treatment of Common Warts
NCT04399577Phase 2
Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts
NCT03853785Phase 3
Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts
NCT03158168Phase 3
Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts
NCT00569231Phase 1
Study With Candida Antigen for Treatment of Warts
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5